logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9751885 B1

PDFFull Text
Date of Patent:
Sep. 05, 2017

Filed:

Oct. 11, 2013

Cyclopropanamine compound and use thereof

Applicant:

Takeda Pharmaceutical Company Limited, Osaka-shi, Osaka, JP;

Inventors:

Naoki Tomita, Tokyo, JP;

Daisuke Tomita, Kanagawa, JP;

Yusuke Tominari, Kanagawa, JP;

Shinichi Imamura, Kanagawa, JP;

Shinji Morimoto, Kanagawa, JP;

Takuto Kojima, Kanagawa, JP;

Masashi Toyofuku, Kanagawa, JP;

Yasushi Hattori, Kanagawa, JP;

Tomohiro Kaku, Kanagawa, JP;

Mitsuhiro Ito, Kanagawa, JP;

Assignee:

Takeda Pharmaceutical Company Limited, Osaka, JP;

Attorney:

Hamre, Schumann, Mueller & Larson, P.C.

Primary Examiner:

Heidi Reese

Int. Cl.
CPC ...
C07D 487/04 (2006.01); C07C 255/58 (2006.01); C07C 255/60 (2006.01); C07D 231/40 (2006.01); C07C 317/40 (2006.01); C07C 237/30 (2006.01); C07C 237/38 (2006.01); C07C 237/40 (2006.01); C07C 255/29 (2006.01); A61K 45/06 (2006.01); C07D 309/14 (2006.01); C07D 319/18 (2006.01); C07D 413/12 (2006.01); C07D 241/12 (2006.01); C07D 417/12 (2006.01); C07D 261/14 (2006.01); C07D 207/12 (2006.01); C07D 285/135 (2006.01); C07D 211/58 (2006.01); C07D 295/135 (2006.01); C07D 213/40 (2006.01); C07D 207/46 (2006.01); C07D 213/36 (2006.01); C07D 223/12 (2006.01); C07D 231/38 (2006.01); C07D 241/18 (2006.01); C07D 265/36 (2006.01); C07D 277/38 (2006.01); C07D 333/20 (2006.01); C07D 405/12 (2006.01); C07D 471/04 (2006.01); C07D 513/04 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 45/06 (2013.01); C07C 237/30 (2013.01); C07C 237/38 (2013.01); C07C 237/40 (2013.01); C07C 255/29 (2013.01); C07C 255/58 (2013.01); C07C 255/60 (2013.01); C07C 317/40 (2013.01); C07D 207/12 (2013.01); C07D 207/46 (2013.01); C07D 211/58 (2013.01); C07D 213/36 (2013.01); C07D 213/40 (2013.01); C07D 223/12 (2013.01); C07D 231/38 (2013.01); C07D 231/40 (2013.01); C07D 241/12 (2013.01); C07D 241/18 (2013.01); C07D 261/14 (2013.01); C07D 265/36 (2013.01); C07D 277/38 (2013.01); C07D 285/135 (2013.01); C07D 295/135 (2013.01); C07D 309/14 (2013.01); C07D 319/18 (2013.01); C07D 333/20 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 513/04 (2013.01); C07C 2101/02 (2013.01); C07C 2101/04 (2013.01); C07C 2101/08 (2013.01); C07C 2101/14 (2013.01);
Abstract

The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s);

Find Patent Forward Citations

Loading…